Home Cart 0 Sign in  
X

[ CAS No. 95-24-9 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 95-24-9
Chemical Structure| 95-24-9
Chemical Structure| 95-24-9
Structure of 95-24-9 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 95-24-9 ]

Related Doc. of [ 95-24-9 ]

Alternatived Products of [ 95-24-9 ]

Product Details of [ 95-24-9 ]

CAS No. :95-24-9 MDL No. :MFCD00053557
Formula : C7H5ClN2S Boiling Point : -
Linear Structure Formula :- InChI Key :VMNXKIDUTPOHPO-UHFFFAOYSA-N
M.W : 184.65 Pubchem ID :7226
Synonyms :

Calculated chemistry of [ 95-24-9 ]

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 9
Fraction Csp3 : 0.0
Num. rotatable bonds : 0
Num. H-bond acceptors : 1.0
Num. H-bond donors : 1.0
Molar Refractivity : 49.03
TPSA : 67.15 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : Yes
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.4 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.83
Log Po/w (XLOGP3) : 2.85
Log Po/w (WLOGP) : 2.54
Log Po/w (MLOGP) : 1.85
Log Po/w (SILICOS-IT) : 3.07
Consensus Log Po/w : 2.43

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.39
Solubility : 0.076 mg/ml ; 0.000411 mol/l
Class : Soluble
Log S (Ali) : -3.92
Solubility : 0.0223 mg/ml ; 0.000121 mol/l
Class : Soluble
Log S (SILICOS-IT) : -3.23
Solubility : 0.109 mg/ml ; 0.000593 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.11

Safety of [ 95-24-9 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P280-P305+P351+P338 UN#:N/A
Hazard Statements:H312-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 95-24-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 95-24-9 ]
  • Downstream synthetic route of [ 95-24-9 ]

[ 95-24-9 ] Synthesis Path-Upstream   1~22

  • 1
  • [ 95-24-9 ]
  • [ 2942-10-1 ]
YieldReaction ConditionsOperation in experiment
89% With sodium nitrite In 1,2-dichloro-ethane at 110℃; for 60 h; Sealed tube It was added in a closed reaction vessel 0.3mmol 2-amino-6-chlorobenzothiazole, 0.6mmol sodium nitrite, 3mL1,2- dichloroethane,the reaction mixture was stirred at 110 reaction conditions 60 hours.After the reaction was stopped, cooled to room temperature, the reactionmixture was added 10mL diluted with dichloromethane, filtration and stripped ofsolvent under reduced pressure, the residue was purified by columnchromatography, eluent V (petroleum ether) / V (ethyl ester) = 6/1, to give6-chlorobenzothiazole, yield 89percent.
59%
Stage #1: With phosphoric acid; sodium nitrite In water at -10℃; for 2 h;
Stage #2: With hypophosphorous acid In water at -5 - 20℃;
General procedure: Thiazoles (1b-f, j) were prepared from 2-aminothiazoles according to the reported procedure with slight modifications. 24 To a mechanically-stirred solution of 2-amino-6-chlorobenzothiazole (4 g, 21.7 mmol, 1.0 equiv) in 84percent aq phosphoric acid (80 mL) was added a solution of sodium nitrite (9.0 g, 13 mmol, 6.0 equiv) in water (28 mL) dropwise below the surface at -10 °C. After stirring at -10 °C for another 2 h, a 50percent aq solution of hypophosphorous acid (60 mL) was added dropwise to the resulting thick syrup mixture at -5 °C. The reaction mixture was warmed to room temperature, stirred overnight, and then diluted with water (300 mL). Na2CO3 was added portionwise to adjust to pH=8 and extracted with DCM. The organic phase was dried over Na2SO4, concentrated under vacuum, and purified over column chromatography (petroleum ether/EtOAc=100:1) to give 6-chlorobenzothiazole as white solid (2.2 g, 59percent yield).
Reference: [1] Chemical and Pharmaceutical Bulletin, 1998, vol. 46, # 4, p. 623 - 630
[2] Patent: CN105367442, 2016, A, . Location in patent: Paragraph 0018
[3] Chemical and Pharmaceutical Bulletin, 1997, vol. 45, # 9, p. 1547 - 1549
[4] Tetrahedron, 2013, vol. 69, # 22, p. 4436 - 4444
[5] Synthetic Communications, 1980, vol. 10, # 3, p. 167 - 174
[6] Journal of Heterocyclic Chemistry, 2000, vol. 37, # 6, p. 1655 - 1658
[7] Chemical Communications, 2012, vol. 48, # 42, p. 5181 - 5183
[8] Organic Letters, 2013, vol. 15, # 17, p. 4600 - 4603
[9] Tetrahedron, 2014, vol. 70, # 2, p. 245 - 250
[10] Organic and Biomolecular Chemistry, 2017, vol. 15, # 7, p. 1606 - 1611
  • 2
  • [ 95-24-9 ]
  • [ 3622-23-9 ]
Reference: [1] Zhurnal Obshchei Khimii, 1939, vol. 9, p. 409,411[2] Chem. Zentralbl., 1940, vol. 111, # I, p. 545
[3] Journal of the Indian Chemical Society, 1933, vol. 10, p. 563,568
[4] Farmaco, Edizione Scientifica, 1977, vol. 32, p. 348 - 354
[5] Bioorganic and Medicinal Chemistry Letters, 2007, vol. 17, # 14, p. 4022 - 4025
[6] Chemistry and Biodiversity, 2011, vol. 8, # 2, p. 253 - 265
[7] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 9, p. 3044 - 3049
  • 3
  • [ 95-24-9 ]
  • [ 3507-17-3 ]
YieldReaction ConditionsOperation in experiment
69% With tert.-butylnitrite; copper(I) bromide In acetonitrile at 60℃; for 1 h; General procedure: To a stirred suspension of CuBr (1.57 g, 10.9 mmol) in MeCN (25 ml) was added tBuONO (1.63 ml, 13.7 mmol) and the mixture was stirred at 60 °C for 10 min. Then 2-amino-6-methylbenzothiazole (14b) (1.50 g, 9.13 mmol) was added to the mixture, and the reaction mixture was stirred at 60 °C for 1 h. After cooled to room temperature, the mixture was poured into 1 N HCl. The resulting precipitate was dissolved into EtOAc, washed with 1 N HCl, brine, dried over Na2SO4, and evaporated. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc (7:1, v/v) as eluent to give the title compound (703 mg, 34percent) as a brown oil.
Reference: [1] Bioorganic and Medicinal Chemistry, 2012, vol. 20, # 3, p. 1201 - 1212
[2] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 18, p. 5919 - 5923
  • 4
  • [ 95-24-9 ]
  • [ 7787-70-4 ]
  • [ 3507-17-3 ]
YieldReaction ConditionsOperation in experiment
69% With tert.-butylnitrite In hexane; ethyl acetate; acetonitrile (Step 1)
Synthesis of 2-bromo-6-chlorobenzothiazole
Copper (I) bromide (1.40 g, 9.76 mmol) was suspended in acetonitrile (25 ml).
To the resulting suspension was added tert-butyl nitrite (1.45 ml, 12.2 mmol) and the mixture was stirred at 60OEC for 15 minutes.
To the reaction mixture was added 2-amino-6-chlorobenzothiazole (1.50 g, 8.12 mmol), followed by stirring at 60OEC for 30 minutes.
After cooling, the reaction mixture was diluted with ethyl acetate.
The ethyl acetate solution was washed with 1N HCl and saturated brine, dried over anhydrous sodium sulfate, and distilled under reduced pressure to remove the solvent.
The residue was purified by chromatography on a silica gel column, whereby from n-hexane/ethyl acetate (7:1, v/v) eluate fractions, 2-bromo-6-chlorobenzothiazole (1.39 g, 69percent) was obtained as a yellow solid.
1H-NMR (CDCl3) δ: 7.42-7.46 (m, 1H), 7.76-7.90 (m, 2H).
Reference: [1] Patent: EP1346982, 2003, A1,
  • 5
  • [ 333-20-0 ]
  • [ 106-47-8 ]
  • [ 95-24-9 ]
YieldReaction ConditionsOperation in experiment
93%
Stage #1: With nano-BF3/SiO2 In acetonitrile for 0.5 h; Cooling with ice
Stage #2: With bromine In acetonitrile at 0 - 20℃; for 5 h;
General procedure: A solution of substituted aniline (2 mmol) in acetonitrile (15 ml) was added to a solution of KSCN (8 mmol) in acetonitrile (15 ml). Then, 0.06 g (30 mol percent BF3) of nano-BF3/SiO2 was added to the mixture, then was placed in a freezing mixture of ice and salt and mechanically stirred for 30 min. Then, bromine (4 mmol, 0.2 ml) in acetonitrile (3 ml) as solvent was added from a dropping funnel at such a rate that the temperature never rose beyond 0°C. After all the bromine was added at 60 min, the solution was stirred for 4 h at room temperature. The progress of the reaction was monitored by TLC. Then, the mixture was poured into water with stirring and the mixture was heated to 70°C on a steam bath and filtered hot to remove the catalyst and the recovered catalyst was washed with acetone and reused in the reaction. The filtrate was neutralized with 10 percent NaOH solution and the precipitate was collected on a filter, dried and recrystallized from ethanol (10 ml) to afford the corresponding products. All of the 2-aminobenzothiazole products were identified by physical and spectroscopic data as reported below, compared and contrasted with authentic samples.#10;Spectral data for selected products#10;6-Bromo-1,3-benzothiazol-2-amine (2e) Yellow solid; Yield = 93 percent; m.p. =202–204°C; (m.p. = 203°C), FT-IR (KBr)/t(cm-1): 3315, 3012, 2835,1580, 1476, 1261, 920, 742, 512. 1H NMR (400 MHz, CDCl3)/d ppm: 5.44 (s, 2H, NH2) 7.4–7.5 (d, 2H, Ar–H), 7.71 (s, 1H, Ar–H); 13C NMR/(100 MHz, DMSO-d6)/d ppm: 119, 120.9, 125.15, 126.07, 133.1, 152.15, 167.75.#10;
85%
Stage #1: at 15 - 20℃; for 2 h;
Stage #2: at 15 - 20℃;
6.38 g (0.05 mol) of p-chloroaniline was placed in a 100 ml round bottom flask, dissolved in 50 ml of glacial acetic acid, and then 5.40 g (0.055 mol) of potassium thiocyanate was added.Stir at 15-20 ° C for 2 h until the solid disappears completelyThen, 1 ml of bromine acetic acid solution was added dropwise at 15-20 ° C.When the temperature is controlled, the temperature is not more than 20 ° C, and the addition is completed in about 1 h.Normal temperature reaction for 2-4 hours, TLC tracking reaction,After the raw material amine is completely reacted, dissolved in hot water, filtered after a little cold.A white filter droplet is added to add 5 ml of concentrated ammonia water to adjust the pH to neutral or weakly alkaline. During this period, a large amount of white solid precipitates, and after standing, it is filtered, the filter cake is washed with water, and dried under vacuum.7.86 g of a white to slightly yellow powdery solid product are obtained.Melting point: 199-200 ° C, yield 85percent.
72%
Stage #1: at 20℃; Cooling with ice
Stage #2: With ammonium hydroxide In water
General procedure: A mixture of 0.1 mol of 4-substituted aniline and 0.1 mol of Potassium thiocyanate (KCNS) in 100 ml glacial acetic acid (AcOH) was cooled in an ice bath and stirred for 10-20 min, and then 0.1 mol bromine in glacial acetic acid was added dropwise at such a rate to keep the temperature below 10 °C throughout the addition. The reaction mixture was stirred at room temperature for 2-4 h, the hydrobromide (HBr) salt thus separated out was filtered, washed with acetic acid, dried, dissolved in hot water and basified to pH 11.0 with ammonia solution (NH4OH) and the resulting precipitate was filtered, washed with water and dried to get the desired product 3a-k. The progress of the reaction was monitored by Thin Layer Chromatography using toluene: acetone (8:2) solvent system.
68.5%
Stage #1: at -10 - 20℃; for 12.5 h;
Stage #2: With ammonium hydroxide In waterHeating
General procedure: An appropriately p-substituted aniline (0.1 mol) and potassiumthiocyanate (KCNS, 9.718 g, 0.1 mol) were dissolvedin 100 mL of glacial acetic acid (AcOH), cooled inice–salt mixture and stirred mechanically, while a solutionof bromine (15.980 g, 0.1 mol) in AcOH (20 mL)was slowly added drop by drop (Palkar et al. 2010).External cooling was applied throughout the process to keepthe temperature below 10 °C and the stirring was continuedfor 30 min. After all of the bromine had been added, thesolution was stirred for 2 h below room temperature and atroom temperature for 10 h. It was then allowed to standovernight during which the precipitate of imino-benzo[d]thiazole hydrobromide salt thus separated out was filtered,washed with acetic acid, dried, dissolved in hot water andbasified to pH 11.0 with ammonia solution (NH4OH) andthe resulting precipitate was filtered, washed with water anddried to get the desired products 2-amino-6-substitutedbenzo[d]thiazole (1a–d). The progress of the reaction wasmonitored by TLC using acetone (20percent) in toluene solvent.
57.58% at 10 - 20℃; for 3 h; To a solution of 4-chloroaniline (3.0g, 23.52mmol, l .Oeq) in acetic acid (90mL) were added Potassium thiocyanate (2.28g, 23.52mmol, l .Oeq). The reaction mixture was cooled at 10°C and bromine solution (3.76g, 23.52mmol, l .Oeq) was added dropwise. Reaction mixture was further stirred at room temperature for 3h. After completion of reaction, reaction mixture was filtered and washed with acetic acid. Filtered solid was heated in water and then neutralized with aqueous ammonia to obtain solid which was filtered and dried well to obtain pure 118.1. (2.5g, 57.58percent). MS(ES): m/z 185.64 [M+H]+
42% at 25 - 35℃; for 20 h; General procedure: A solution of bromine (0.26mL, 10.0mmol) in acetic acid (5.0mL)was added over about 30 min to a mixture of aromatic amine(10.0 mmol) and potassium thiocyanate (1.07 g, 11.0 mmol) in aceticacid (20 mL), the temperature being kept between 25 and 35 °C. The slurry was then stirred for 20 h at room temperature. The precipitate was filtered, washed with a little acetic acid, slurried in water, made neutral with aqueous ammonia, and filtered again. The residue was boiled for 20 min with excess of hydrochloric acid (15percent v:v) and the hot mixture was filtered from impurities. The filtrate, cooled to 10 °C,was made alkaline with aqueous ammonia and the precipitate was filtered,washed, and dried. The crude product was recrystallized from ethanol–water to afford I–IV, respectively.

Reference: [1] Synlett, 2012, vol. 23, # 15, p. 2219 - 2222
[2] Research on Chemical Intermediates, 2016, vol. 42, # 12, p. 7855 - 7868
[3] Journal of Organic Chemistry, 2017, vol. 82, # 18, p. 9312 - 9320
[4] Patent: CN108623537, 2018, A, . Location in patent: Paragraph 0104; 0105
[5] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2010, vol. 49, # 6, p. 818 - 825
[6] Phosphorus, Sulfur and Silicon and the Related Elements, 2008, vol. 183, # 5, p. 1124 - 1133
[7] Journal of the Indian Chemical Society, 2008, vol. 85, # 3, p. 333 - 335
[8] European Journal of Medicinal Chemistry, 2008, vol. 43, # 5, p. 1114 - 1122
[9] Archiv der Pharmazie, 2015, vol. 348, # 4, p. 254 - 265
[10] European Journal of Medicinal Chemistry, 2012, vol. 53, p. 41 - 51
[11] Medicinal Chemistry Research, 2017, vol. 26, # 9, p. 1969 - 1987
[12] Patent: WO2018/71794, 2018, A1, . Location in patent: Paragraph 00630; 00631
[13] Journal of Molecular Liquids, 2013, vol. 188, p. 173 - 177
[14] Polish Journal of Chemistry, 1996, vol. 70, # 10, p. 1250 - 1256
[15] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 11, p. 3443 - 3446
[16] Archiv der Pharmazie, 2010, vol. 343, # 6, p. 353 - 359
[17] Journal of Enzyme Inhibition and Medicinal Chemistry, 2011, vol. 26, # 3, p. 332 - 340
[18] Patent: WO2011/151361, 2011, A1, . Location in patent: Page/Page column 43-44
[19] Asian Journal of Chemistry, 2011, vol. 23, # 9, p. 3969 - 3974
[20] Journal of the Korean Chemical Society, 2012, vol. 56, # 2, p. 251 - 256
[21] Asian Journal of Chemistry, 2011, vol. 23, # 11, p. 5133 - 5136
[22] Asian Journal of Chemistry, 2010, vol. 22, # 7, p. 5487 - 5492
[23] Heteroatom Chemistry, 2012, vol. 23, # 4, p. 399 - 410
[24] Medicinal Chemistry Research, 2012, vol. 21, # 9, p. 2661 - 2670
[25] Organic Letters, 2012, vol. 14, # 20, p. 5334 - 5337,4
[26] Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, vol. 28, # 1, p. 1 - 10
[27] European Journal of Medicinal Chemistry, 2013, vol. 67, p. 1 - 13
[28] European Journal of Medicinal Chemistry, 2014, vol. 71, p. 24 - 30
[29] Archiv der Pharmazie, 2013, vol. 346, # 11, p. 819 - 831
[30] Journal of Heterocyclic Chemistry, 2014, vol. 51, # 2, p. 459 - 465
[31] Combinatorial Chemistry and High Throughput Screening, 2013, vol. 16, # 3, p. 244 - 247
[32] Medicinal Chemistry, 2013, vol. 9, # 4, p. 596 - 607
[33] Journal of Heterocyclic Chemistry, 2014, vol. 51, # 6, p. 1641 - 1658
[34] Research on Chemical Intermediates, 2015, vol. 41, # 8, p. 5599 - 5609
[35] Bioorganic and Medicinal Chemistry Letters, 2015, vol. 25, # 23, p. 5561 - 5565
[36] Synthetic Communications, 2016, vol. 46, # 2, p. 169 - 178
[37] Bioorganic Chemistry, 2016, vol. 67, p. 130 - 138
[38] Journal of Heterocyclic Chemistry, 2017, vol. 54, # 2, p. 1327 - 1341
[39] Journal of Heterocyclic Chemistry, 2017, vol. 54, # 6, p. 3282 - 3293
[40] Fortschr. Teerfarbenfabr. Verw. Industriezweige, vol. 16, p. 2568
[41] Archiv der Pharmazie, 2018, vol. 351, # 12,
  • 6
  • [ 3696-23-9 ]
  • [ 95-24-9 ]
YieldReaction ConditionsOperation in experiment
43.1% With bromine In chloroform; water at 50 - 70℃; for 9 h; The chlorothiourea (8.50 g, 45.70 mmol) was added to a 250 mL eggplant-shaped flask and dissolved in 50.00 mL of chloroform.Reflow under a 50 ° C oil bath for 20 minutes,After the reaction solution is placed in an ice water bath,Slowly add bromine (2.58 mL, 50.27 mmol),After stirring for 5 minutes, transfer back to the oil bath.Raise the temperature to 70 ° C and continue to reflux.The progress of the reaction was monitored by thin layer chromatography and the reaction was complete after 9 h.After cooling to room temperature, a solid precipitated and was filtered under reduced pressure.Slowly add ammonia water to the filtrate.Adjust the pH to neutral and a white precipitate will form.After stirring for 5 minutes, the mixture was filtered under reduced pressure, and the solid was washed twice,Vacuum drying to constant weight,Obtained white solid 3.62g,The yield was 43.10percent.
Reference: [1] Patent: CN108358869, 2018, A, . Location in patent: Paragraph 0035; 0036
[2] Journal of the Chemical Society, 1927, p. 1190
[3] Journal of the Indian Chemical Society, 1931, vol. 8, p. 147,163
[4] Journal fuer Praktische Chemie (Leipzig), 1974, vol. 316, p. 154 - 158
[5] Journal of the Chemical Society [Section] C: Organic, 1969, p. 268 - 272
[6] Journal of the Indian Chemical Society, 1989, vol. 66, p. 39 - 41
[7] Farmaco, Edizione Scientifica, 1982, vol. 37, # 3, p. 205 - 212
[8] Patent: US4563533, 1986, A,
[9] Acta Poloniae Pharmaceutica - Drug Research, 2009, vol. 66, # 4, p. 387 - 392
[10] Research on Chemical Intermediates, 2010, vol. 36, # 8, p. 985 - 993
[11] Asian Journal of Chemistry, 2012, vol. 24, # 6, p. 2747 - 2752
[12] Research on Chemical Intermediates, 2013, vol. 39, # 6, p. 2555 - 2564
[13] Medicinal Chemistry Research, 2013, vol. 22, # 9, p. 4211 - 4222
[14] Medicinal Chemistry Research, 2013, vol. 22, # 9, p. 4316 - 4321
[15] Research on Chemical Intermediates, 2015, vol. 41, # 9, p. 6141 - 6148
[16] Chemical Biology and Drug Design, 2016, p. 354 - 362
[17] Journal of Medicinal Chemistry, 2016, vol. 59, # 21, p. 9814 - 9824
[18] Russian Journal of General Chemistry, 2017, vol. 87, # 12, p. 3006 - 3016
[19] Journal of Heterocyclic Chemistry, 2018, vol. 55, # 11, p. 2507 - 2515
  • 7
  • [ 106-47-8 ]
  • [ 95-24-9 ]
YieldReaction ConditionsOperation in experiment
67%
Stage #1: at 10℃;
Stage #2: at 10 - 20℃; for 4 h;
General procedure: A mixture of aniline (0.05mol) and NH4SCN (19.03g, 0.25mol) in glacial acetic acid (100mL) was cooled to 10°C in an ice bath and stirred for 10–20min. Then bromine (2.82mL, 0.055mol) in glacial acetic acid was added drop wise at such a rate to keep the temperature below 10°C. The mixture was stirred at room temperature for 4h and then poured into hot water (500mL), and basified to pH 11.0 with ammonia solution (NH4OH). The resulting precipitate was filtered, washed with water and dried to get a light yellow to brown solid. The crude product was purified by chromatography on silica gel using MeOH/CH2Cl2 to afford compounds 2a–2k in good yields.
Reference: [1] Chemistry of Heterocyclic Compounds, 2009, vol. 45, # 11, p. 1343 - 1353
[2] Bioorganic and Medicinal Chemistry, 2018, vol. 26, # 8, p. 1759 - 1775
[3] European Journal of Medicinal Chemistry, 2010, vol. 45, # 9, p. 4293 - 4299
[4] Archiv der Pharmazie, 2010, vol. 343, # 11-12, p. 692 - 699
  • 8
  • [ 1147550-11-5 ]
  • [ 106-47-8 ]
  • [ 95-24-9 ]
Reference: [1] Journal of Organic Chemistry, 2018, vol. 83, # 19, p. 12129 - 12142
[2] European Journal of Organic Chemistry, 2011, # 31, p. 6206 - 6217
[3] Heterocyclic Communications, 2002, vol. 8, # 3, p. 275 - 280
[4] Medicinal Chemistry Research, 2011, vol. 20, # 7, p. 1033 - 1041
[5] Bioorganic and Medicinal Chemistry Letters, 2007, vol. 17, # 14, p. 4022 - 4025
[6] Chemische Berichte, 1934, vol. 67, p. 944,947
[7] Journal of Enzyme Inhibition and Medicinal Chemistry, 2011, vol. 26, # 4, p. 527 - 534
[8] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 9, p. 3044 - 3049
[9] Archiv der Pharmazie, 2016, p. 651 - 661
[10] European Journal of Medicinal Chemistry, 2018, vol. 148, p. 477 - 486
[11] International Journal of Pharmacy and Pharmaceutical Sciences, 2018, vol. 10, # 10, p. 57 - 61
  • 9
  • [ 1367199-79-8 ]
  • [ 95-24-9 ]
Reference: [1] Archiv der Pharmazie, 2009, vol. 342, # 8, p. 462 - 468
[2] Medicinal Chemistry Research, 2013, vol. 22, # 1, p. 195 - 210
[3] Medicinal Chemistry Research, 2013, vol. 22, # 9, p. 4211 - 4222
[4] Journal of Chemical Research, 2014, vol. 38, # 10, p. 611 - 616
  • 10
  • [ 106-47-8 ]
  • [ 95-24-9 ]
Reference: [1] Journal of Heterocyclic Chemistry, 1981, vol. 18, # 4, p. 759 - 761
  • 11
  • [ 106-47-8 ]
  • [ 95-24-9 ]
Reference: [1] Chinese Journal of Chemistry, 2016, vol. 34, # 11, p. 1081 - 1085
  • 12
  • [ 106-47-8 ]
  • [ 95-24-9 ]
Reference: [1] Journal of the Chemical Society [Section] C: Organic, 1969, p. 268 - 272
[2] Research on Chemical Intermediates, 2010, vol. 36, # 8, p. 985 - 993
[3] Letters in Drug Design and Discovery, 2011, vol. 8, # 9, p. 717 - 724
[4] Letters in Drug Design and Discovery, 2011, vol. 8, # 8, p. 717 - 724
[5] Asian Journal of Chemistry, 2012, vol. 24, # 6, p. 2747 - 2752
[6] Medicinal Chemistry Research, 2013, vol. 22, # 1, p. 195 - 210
[7] Research on Chemical Intermediates, 2013, vol. 39, # 6, p. 2555 - 2564
[8] Medicinal Chemistry Research, 2013, vol. 22, # 9, p. 4211 - 4222
[9] Journal of Chemical Research, 2014, vol. 38, # 10, p. 611 - 616
[10] Chemical Biology and Drug Design, 2016, p. 354 - 362
[11] Journal of Medicinal Chemistry, 2016, vol. 59, # 21, p. 9814 - 9824
[12] Russian Journal of General Chemistry, 2017, vol. 87, # 12, p. 3006 - 3016
[13] Patent: CN108358869, 2018, A,
[14] Journal of Heterocyclic Chemistry, 2018, vol. 55, # 11, p. 2507 - 2515
  • 13
  • [ 333-20-0 ]
  • [ 62-53-3 ]
  • [ 95-24-9 ]
Reference: [1] Medicinal Chemistry Research, 2013, vol. 22, # 7, p. 3316 - 3328
  • 14
  • [ 540-72-7 ]
  • [ 106-47-8 ]
  • [ 95-24-9 ]
Reference: [1] Die Pharmazie, 1967, vol. 22, # 6, p. 229 - 233
[2] Patent: US2212175, 1939, ,
  • 15
  • [ 1280582-67-3 ]
  • [ 95-24-9 ]
Reference: [1] Letters in Drug Design and Discovery, 2011, vol. 8, # 9, p. 717 - 724
[2] Letters in Drug Design and Discovery, 2011, vol. 8, # 8, p. 717 - 724
  • 16
  • [ 14779-13-6 ]
  • [ 95-24-9 ]
Reference: [1] Chemische Berichte, 1967, vol. 100, # 5, p. 1394 - 1401
  • 17
  • [ 20265-96-7 ]
  • [ 95-24-9 ]
Reference: [1] Medicinal Chemistry Research, 2013, vol. 22, # 9, p. 4211 - 4222
  • 18
  • [ 5407-51-2 ]
  • [ 95-24-9 ]
Reference: [1] Archiv der Pharmazie (Weinheim, Germany), 1935, vol. 273, p. 31,50
  • 19
  • [ 103-85-5 ]
  • [ 95-24-9 ]
Reference: [1] Patent: US1984885, 1931, ,
[2] Patent: US1984885, 1931, ,
  • 20
  • [ 136-95-8 ]
  • [ 95-24-9 ]
Reference: [1] Fortschr. Teerfarbenfabr. Verw. Industriezweige, vol. 18, p. 493
  • 21
  • [ 1111-67-7 ]
  • [ 106-47-8 ]
  • [ 95-24-9 ]
Reference: [1] Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1988, vol. 27, # 1-12, p. 189 - 190
  • 22
  • [ 95-24-9 ]
  • [ 62266-81-3 ]
Reference: [1] Farmaco, Edizione Scientifica, 1977, vol. 32, p. 348 - 354
Same Skeleton Products
Historical Records